Is KPRX or KRYS more undervalued in 2026?

CirclFi compares Kiora Pharmaceuticals, Inc. (KPRX) and Krystal Biotech, Inc. (KRYS) using 13 institutional-grade valuation models. KPRX has a Quality of Company score of 5.5/10 while KRYS scores 7.7/10.

Which is a better buy — KPRX or KRYS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do KPRX and KRYS valuations compare?

KPRX at $2.83 and KRYS at $310.30 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

KPRX vs KRYS Valuation Comparison 2026 — Intrinsic Value Analysis

KPRX

Biotechnology

Kiora Pharmaceuticals, Inc.

Quality

5.5

out of 10

Value Trap

LOW

Price

$2.83

Last close

Models

9/13

Active

KRYS

Biotechnology

Krystal Biotech, Inc.

Quality

7.7

out of 10

Value Trap

SAFE

Price

$310.30

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	KPRX Fair Value	KPRX Upside	KRYS Fair Value	KRYS Upside
Bayesian DCF	Intrinsic	$2.06	-27.1%	$137.31	-55.8%
Earnings Power Value	Intrinsic	—	—	$61.44	-80.2%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.48	-80.2%	$137.20	-55.8%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for KPRX vs KRYS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

KPRX vs KRYS — Which Stock Is More Undervalued?

KRYS scores higher with a 7.7/10 quality rating vs KPRX's 5.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Kiora Pharmaceuticals, Inc. (KPRX) and Krystal Biotech, Inc. (KRYS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

KPRX currently trades at $2.83 with a QOC of 5.5/10, while KRYS trades at $310.30 with a QOC of 7.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).